Leaderboards/Autoimmune Bullous Skin Diseases

Autoimmune Bullous Skin Diseases

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Hanan Rashid
University Medical Center Groningen
2
Valentina Raglianti
European Society for Sexual Medicine
3
Meagan E. Chriswell
University of Colorado Anschutz Medical Campus
4
А.Ш. Иноятов
Unknown
5
Bladimir Rodríguez-Lechtig
Universidad El Bosque
6
Su‐Chi Ku
Taipei Medical University Hospital
7
Fagui Zou
Sun Yat-sen University
8
Joannu Ann Varughese
Leicester Royal Infirmary
9
Dimitra Aikaterini Lintzeri
Humboldt-Universität zu Berlin
10
Maud Maho‐Vaillant
Inserm

Papers

1
Anti-slit diaphragm antibodies on kidney biopsy identify pediatric patients with steroid-resistant nephrotic syndrome responsive to second-line immunosuppressants
Kidney International|2024
61 cit.
2
Invasive group A streptococcal disease
BMJ Case Reports|2024
53 cit.
3
Anti-slit Antibodies against Podocin and Kirrel1 in Pediatric and Adult Podocytopathies
Journal of the American Society of Nephrology|2025
37 cit.
4
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: biological challenges and clinical implications
Nephrology Dialysis Transplantation|2025
7 cit.
5
Publication in British Journal of Dermatology (2025) [4 citations, W4407898056]
British Journal of Dermatology|2025
4 cit.
6
Anti-slit Antibodies on Kidney Biopsy Identify Patients with Steroid-Resistant Nephrotic Syndrome Responsive to Second-Line Immunosuppressant and Hence Have a Good Prognosis
Journal of the American Society of Nephrology|2024
1 cit.
7
Anti-podocin Enzyme-Linked Immunosorbent Assay Guides Immunotherapy in Steroid-Resistant Nephrotic Syndrome
Kidney International Reports|2025
1 cit.
8
Publication in Nephrology Dialysis Transplantation (2024) [W4398235296]
Nephrology Dialysis Transplantation|2024
0 cit.
9
Publication in Annales de Dermatologie et de Vénéréologie - FMC (2024) [W4404348190]
Annales de Dermatologie et de Vénéréologie - FMC|2024
0 cit.
10
Publication in Journal of Investigative Dermatology (2024) [W4404535164]
Journal of Investigative Dermatology|2024
0 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Samantha C. Gordon
Northwestern University
2
Vidhya Hariharan
American Academy of Dermatology
3
Kshama Mehta
Massachusetts General Hospital
4
Ron J. Feldman
Emory University
5
Julia Spoendlin
University Hospital of Basel
6
Chao Ji
Zhongshan Hospital of Xiamen University
7
Anita Lavery
The Northern Ireland Cancer Centre
8
Hagen Staude
University of Rostock
9
Thomas Rauen
RWTH Aachen University
10
Rocío Lledó‐García
UCB Pharma (United Kingdom)

Papers

1
Efficacy and tolerability of oral upadacitinib monotherapy in patients with recalcitrant vitiligo
Journal of the American Academy of Dermatology|2023
47 cit.
2
An observational study of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab
Journal of the American Academy of Dermatology|2023
15 cit.
3
Clinical Features of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor versus Non-Immune Checkpoint Inhibitor Drugs in China: A Cross-Sectional Study and Literature Review
Journal of Inflammation Research|2024
9 cit.
4
Use of metamizole and other non-opioid analgesics in Switzerland between 2014 and 2019: an observational study using a large health insurance claims database
Swiss Medical Weekly|2024
8 cit.
5
Efficacy and safety of switching from baricitinib to ritlecitinib in severe alopecia areata
Clinical and Experimental Dermatology|2024
8 cit.
6
Application and Comparison of Dermoscopy and Reflectance Confocal Microscopy in the Target Treatment of Genital Lichen Sclerosus: A Single-Arm Prospective Study
Dermatology and Therapy|2023
5 cit.
7
Multiple cutaneous myxofibrosarcoma on the right arm: Clinicopathological features and differential diagnosis
Clinical Case Reports|2024
4 cit.
8
Dispensed drugs during pregnancy in outpatient care between 2015 and 2021 in Switzerland: a retrospective analysis of Swiss healthcare claims data
Swiss Medical Weekly|2024
4 cit.
9
Changes in the Use of Hydrochlorothiazide and Other Antihypertensive Drugs in Switzerland in Association With the Swissmedic Safety Alert Regarding Non‐melanoma Skin Cancer: An Interrupted Time‐Series Analysis Using Swiss Claims Data
Pharmacoepidemiology and Drug Safety|2024
4 cit.
10
Comparative Efficacy and Safety of Ustekinumab and Secukinumab in the Treatment of Generalized Pustular Psoriasis: A 48-Week Retrospective Cohort Study with Genetic Background Analysis
Journal of Inflammation Research|2024
4 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Robert Winchester
Columbia University Irving Medical Center
2
Luis A. Díaz
Memorial Sloan Kettering Cancer Center
3
Jouni Uitto
Thomas Jefferson University
4
Takashi Hashimoto
Osaka Metropolitan University
5
Detlef Zillikens
University of Lübeck
6
Marcus Maurer
Humboldt-Universität zu Berlin
7
Enno Schmidt
Carrier (United States)
8
Michael Hertl
Universitätsklinikum Gießen und Marburg
9
Masayuki Amagai
Keio University
10
James N. George
University of Oklahoma

Papers

1
The 1982 revised criteria for the classification of systemic lupus erythematosus
Arthritis & Rheumatism|1982
14.6k cit.
2
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine|2015
9.4k cit.
3
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Science|2017
6.6k cit.
4
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Science Translational Medicine|2014
5.1k cit.
5
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Journal of Clinical Oncology|2019
3k cit.
6
Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer
New England Journal of Medicine|2020
3k cit.
7
Circulating mutant DNA to assess tumor dynamics
Nature Medicine|2008
2.7k cit.
8
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
Blood|2008
2.7k cit.
9
The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Nature|2012
1.7k cit.
10
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer
New England Journal of Medicine|2022
1.5k cit.

Reagents for Autoimmune Bullous Skin Diseases

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 65

Acetyl-alpha-Tubulin (Lys40) (D20G3) Rabbit Monoclonal Antibody (SignalFlex™ mFluor™ UV375 Conjugate)

Cited in 5 papers
#19913$486
View Evidence →
Agilent/DakoEvidence 65

IgG

#F0202
View Evidence →
Agilent/DakoEvidence 65

IgG

#A0423
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

Sin1 (D7G1A) Rabbit Monoclonal Antibody

Cited in 8 papers
#12860$161,351
View Evidence →
Cell Signaling Technology

PTMScan® HS Asymmetric Di-Methyl Arginine Motif (adme-R) Kit

Cited in 7 papers
#18303$2,540
View Evidence →
Agilent/Dako

C3c Complement

Cited in 6 papers
#F0201
View Evidence →